Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07678567 · ClinicalTrials.gov registry record

Pomegranate Dietary Supplements in AUD and ALD

A clinical trial, sponsored by University of Louisville.

Not yet
Registry status
144
Enrollment target

NCT07678567: Clinical Trial study, sponsored by University of Louisville.

NCT07678567 is a clinical trial that has not yet begun recruiting, run by University of Louisville. The registered enrollment target is 144 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07678567 has not yet begun recruiting, sponsored by University of Louisville.

NOT YET RECRUITING
Registry status
144 participants
Enrollment target

Study Summary

The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate dietary supplements. Recent publications have reported that urolithins are the major active metabolites responsible for the beneficial effects of eating pomegranates, berries, or walnuts. However, the production of urolithins from the parent compound ellagic acid (EA) is dependent upon the presence of certain bacteria in the human gut. In this trial, we propose to investigate variations in gut microbiota and their capacity to metabolize pomegranate dietary supplements (PDS) into active urolithins. We will measure the levels of urolithins in blood as well as inflammatory cytokines in plasma samples upon consumption of PDS.

Primary Outcome

To evaluate the impact of pomegranate dietary supplements (PDS) on gut microbiome composition and epithelial barrier function in healthy, alcohol use disorder (AUD), early-stage ALD (eALD), and alcohol-associated liver cirrhosis (AC) subjects by characterizing the metabolite and cytokine profiles to inform future trials designed for enhancing cut barrier function in alcohol-associated liver disease (ALD).

Interventions

  • DIETARY_SUPPLEMENT Pomegranate Dietary Ssupplement

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2027-01-01
Est. Completion 2032-12-31
University of Louisville

217 total trials

What is known before NCT07678567 opens enrollment

NCT07678567 is an observational study that tracks outcomes without assigning an intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which Pomegranate Dietary Ssupplement is the first listed.

NCT07678567 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07678567 about?

NCT07678567 is a clinical study titled "Pomegranate Dietary Supplements in AUD and ALD". The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate dietary supplements. Recent publications have reported that urolithins are the major active metabolites responsible for the beneficial effec...

What is the current status of trial NCT07678567?

This trial is currently not yet recruiting. The enrollment target is 144 participants. The study started on 2027-01-01. Estimated completion is 2032-12-31.

What interventions are being tested in trial NCT07678567?

The interventions under investigation include: Pomegranate Dietary Ssupplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07678567?

This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07678567, the US trial registry maintained by the National Library of Medicine. NCT07678567 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.